免疫抑制药物建议与新冠病毒病：我们是否弊大于利？
Immunosuppression drug advice and COVID-19: are we doing more harm than good?
作者信息
Warraich Rabia, Amani Lisa, Mediwake Rapti, Tahir Hasan
机构信息
Department of General Medicine, Barnet Hospital, Royal Free London NHS Foundation Trust, London, UK.
Department of Rheumatology and General Medicine, Barnet Hospital, Royal Free London NHS Foundation Trust, London, UK.
出版信息
Br J Hosp Med (Lond). 2020 Jun 2;81(6):1-3. doi: 10.12968/hmed.2020.0312. Epub 2020 Jun 22.
The National Institute for Health and Care Excellence guidelines advise stopping immunosuppressive drugs for confirmed or suspected COVID-19 patients with autoimmune and inflammatory disorders. This may not be in the patient's best interest, given the potential long-term consequences of not managing chronic conditions, and immunosuppression may even be protective in those affected with COVID-19.
英国国家卫生与临床优化研究所的指南建议，对于确诊或疑似患有自身免疫性和炎症性疾病的新冠肺炎患者，应停用免疫抑制药物。考虑到不控制慢性病可能产生的长期后果，这样做可能不符合患者的最佳利益，而且免疫抑制甚至可能对感染新冠肺炎的患者有保护作用。
Zotero 插件